Computational immunogenomic approaches to predict response to cancer immunotherapies.

Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118–122 (2014).

pubmed: 24670642 doi: 10.1038/nature13121

Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).

pubmed: 26558876 pmcid: 4892769 doi: 10.1097/COC.0000000000000239

McDermott, D., Haanen, J., Chen, T. T., Lorigan, P. & O’Day, S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol. 24, 2694–2698 (2013).

pubmed: 23942774 doi: 10.1093/annonc/mdt291

Eggermont, A. M. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).

pubmed: 27717298 doi: 10.1056/NEJMoa1611299

Hammers, H. J. et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J. Clin. Oncol. 35, 3851–3858 (2017).

pubmed: 28678668 pmcid: 7587408 doi: 10.1200/JCO.2016.72.1985

Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

pubmed: 26406148 pmcid: 5719487 doi: 10.1056/NEJMoa1510665

Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

pubmed: 28734759 pmcid: 6207072 doi: 10.1016/S1470-2045(17)30422-9

Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

pubmed: 26028407 pmcid: 4681400 doi: 10.1056/NEJMoa1504627

Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–319 (2014).

pubmed: 25482239 doi: 10.1056/NEJMoa1411087

Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312–322 (2017).

pubmed: 28131785 doi: 10.1016/S1470-2045(17)30065-7

El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).

pubmed: 28434648 pmcid: 7539326 doi: 10.1016/S0140-6736(17)31046-2

Chen, R. et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J. Clin. Oncol. 35, 2125–2132 (2017).

pubmed: 28441111 pmcid: 5791843 doi: 10.1200/JCO.2016.72.1316

Diaz, L. et al. 386P—efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann. Oncol. 28, v128–v129 (2017).

doi: 10.1093/annonc/mdx367.020

Chung, H. C. et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 37, 1470–1478 (2019).

pubmed: 30943124 doi: 10.1200/JCO.18.01265

Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940–952 (2018).

pubmed: 29875066 doi: 10.1016/S1470-2045(18)30351-6

Nghiem, P. et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J. Clin. Oncol. 37, 693–702 (2019).

pubmed: 30726175 pmcid: 6424137 doi: 10.1200/JCO.18.01896

Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 18, 623–630 (2017).

pubmed: 28291584 doi: 10.1016/S1470-2045(17)30169-9

Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847 (2015).

pubmed: 25695955 doi: 10.1158/1535-7163.MCT-14-0983

Duffy, M. J. & Crown, J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin. Chem. 65, 1228–1238 (2019).

pubmed: 31315901 doi: 10.1373/clinchem.2019.303644

Fundytus, A., Booth, C. M. & Tannock, I. F. How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. Ann. Oncol. 32, 833–836 (2021).

pubmed: 33839260 doi: 10.1016/j.annonc.2021.03.208

Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).

pubmed: 29658845 pmcid: 7193684 doi: 10.1056/NEJMoa1801946

Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).

pubmed: 32919526 doi: 10.1016/S1470-2045(20)30445-9

FDA. FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (2020).

Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).

pubmed: 26997480 pmcid: 4808437 doi: 10.1016/j.cell.2016.02.065

Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017).

pubmed: 28650338 pmcid: 5531419 doi: 10.1172/JCI91190

Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).

pubmed: 30309915 pmcid: 6718162 doi: 10.1126/science.aar3593

Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207 (2015).

pubmed: 26359337 pmcid: 5054517 doi: 10.1126/science.aad0095

Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916–1927 (2019).

pubmed: 31792460 pmcid: 6898788 doi: 10.1038/s41591-019-0654-5

Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124 (2015).

pubmed: 25765070 pmcid: 4993154 doi: 10.1126/science.aaa1348

Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat. Cancer 1, 99–111 (2020).

pubmed: 32984843 pmcid: 7514475 doi: 10.1038/s43018-019-0008-8

McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463 (2016).

pubmed: 26940869 pmcid: 4984254 doi: 10.1126/science.aaf1490

Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449–1458 (2018).

pubmed: 30013197 doi: 10.1038/s41591-018-0101-z

Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 8971 (2015).

pubmed: 26634437 doi: 10.1038/ncomms9971

Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).

pubmed: 22544022 pmcid: 4383288 doi: 10.1038/nbt.2203

Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinformatics 56, 15.19.11–15.19.17 (2016).

doi: 10.1002/cpbi.17

Song, S. et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS ONE 7, e45835 (2012).

pubmed: 23049875 pmcid: 3457972 doi: 10.1371/journal.pone.0045835

Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).

pubmed: 24113773 doi: 10.1038/ncomms3612

Revkov, E., Kulshrestha, T., Sung, K. W. & Skanderup, A. J. PUREE: accurate pan-cancer tumor purity estimation from gene expression data. Commun. Biol. 6, 394 (2023).

pubmed: 37041233 pmcid: 10090153 doi: 10.1038/s42003-023-04764-8

Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239–2254.e39 (2021).

pubmed: 33831375 pmcid: 8054914 doi: 10.1016/j.cell.2021.03.009

Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525–533 (2023).

pubmed: 37046096 pmcid: 10115649 doi: 10.1038/s41586-023-05783-5

Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).

pubmed: 28445112 doi: 10.1056/NEJMoa1616288

Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).

pubmed: 24633410 pmcid: 4864026 doi: 10.1038/nmeth.2883

Miller, C. A. et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10, e1003665 (2014).

pubmed: 25102416 pmcid: 4125065 doi: 10.1371/journal.pcbi.1003665

Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).

pubmed: 22608083 pmcid: 3428864 doi: 10.1016/j.cell.2012.04.023

Zaccaria, S. & Raphael, B. J. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data. Nat. Commun. 11, 4301 (2020).

pubmed: 32879317 pmcid: 7468132 doi: 10.1038/s41467-020-17967-y

Xiao, Y. et al. FastClone is a probabilistic tool for deconvoluting tumor heterogeneity in bulk-sequencing samples. Nat. Commun. 11, 4469 (2020).

pubmed: 32901013 pmcid: 7478963 doi: 10.1038/s41467-020-18169-2

Salcedo, A. et al. Crowd-sourced benchmarking of single-sample tumour subclonal reconstruction. Preprint at https://doi.org/10.1101/2022.06.14.495937 (2022).

Tanner, G., Westhead, D. R., Droop, A. & Stead, L. F. Benchmarking pipelines for subclonal deconvolution of bulk tumour sequencing data. Nat. Commun. 12, 6396 (2021).

pubmed: 34737285 pmcid: 8569188 doi: 10.1038/s41467-021-26698-7

Martinez-Ruiz, C. et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature 616, 543–552 (2023).

pubmed: 37046093 pmcid: 10115639 doi: 10.1038/s41586-023-05706-4

Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808–1825 (2020).

pubmed: 33139244 pmcid: 7710563 doi: 10.1158/2159-8290.CD-20-0522

Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

pubmed: 28596308 pmcid: 5576142 doi: 10.1126/science.aan6733

Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

pubmed: 26028255 pmcid: 4481136 doi: 10.1056/NEJMoa1500596

Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

pubmed: 25409260 pmcid: 4315319 doi: 10.1056/NEJMoa1406498

Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).

pubmed: 29262275 pmcid: 6549688 doi: 10.1056/NEJMc1713444

Newell, F. et al. Comparative genomics provides etiologic and biological insight into melanoma subtypes. Cancer Discov. 12, 2856–2879 (2022).

pubmed: 36098958 pmcid: 9716259 doi: 10.1158/2159-8290.CD-22-0603

Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949.e16 (2017).

pubmed: 29033130 pmcid: 5685550 doi: 10.1016/j.cell.2017.09.028

Newell, F. et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 40, 88–102.e107 (2022).

pubmed: 34951955 doi: 10.1016/j.ccell.2021.11.012

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

pubmed: 23945592 pmcid: 3776390 doi: 10.1038/nature12477

Strickler, J. H., Hanks, B. A. & Khasraw, M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin. Cancer Res. 27, 1236–1241 (2021).

pubmed: 33199494 doi: 10.1158/1078-0432.CCR-20-3054

Kassahn, K. S. et al. Somatic point mutation calling in low cellularity tumors. PLoS ONE 8, e74380 (2013).

pubmed: 24250782 pmcid: 3826759 doi: 10.1371/journal.pone.0074380

Xiao, W. et al. Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat. Biotechnol. 39, 1141–1150 (2021).

pubmed: 34504346 pmcid: 8506910 doi: 10.1038/s41587-021-00994-5

Akdemir, K. C. et al. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nat. Genet. 52, 1178–1188 (2020).

pubmed: 33020667 pmcid: 8350746 doi: 10.1038/s41588-020-0708-0

Alioto, T. S. et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat. Commun. 6, 10001 (2015).

pubmed: 26647970 doi: 10.1038/ncomms10001

Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).

pubmed: 32461654 pmcid: 7334197 doi: 10.1038/s41586-020-2308-7

Caron, N. R. et al. Indigenous genomic databases: pragmatic considerations and cultural contexts. Front. Public Health 8, 111 (2020).

pubmed: 32391301 pmcid: 7193324 doi: 10.3389/fpubh.2020.00111

Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).

pubmed: 28636851 pmcid: 6487310 doi: 10.1056/NEJMoa1613493

Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160–1168 (2022).

pubmed: 35708671 pmcid: 9204620 doi: 10.1001/jamaoncol.2022.1981

Aggarwal, C. et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open 6, e2311181 (2023).

pubmed: 37129893 pmcid: 10155064 doi: 10.1001/jamanetworkopen.2023.11181

Buchhalter, I. et al. Size matters: dissecting key parameters for panel-based tumor mutational burden analysis. Int. J. Cancer 144, 848–858 (2019).

pubmed: 30238975 doi: 10.1002/ijc.31878

Ramarao-Milne, P. et al. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open 7, 100540 (2022).

pubmed: 35849877 pmcid: 9463385 doi: 10.1016/j.esmoop.2022.100540

Merino, D. M. et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J. Immunother. Cancer 8, e000147 (2020).

pubmed: 32217756 pmcid: 7174078 doi: 10.1136/jitc-2019-000147

Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69 (2015).

pubmed: 25838375 doi: 10.1126/science.aaa4971

Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598 (2017).

pubmed: 28835386 pmcid: 5670009 doi: 10.1158/1535-7163.MCT-17-0386

Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).

pubmed: 30395155 doi: 10.1093/annonc/mdy495

Yamamoto, T. N., Kishton, R. J. & Restifo, N. P. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat. Med. 25, 1488–1499 (2019).

pubmed: 31591590 doi: 10.1038/s41591-019-0596-y

Lee, C.-H., Yelensky, R., Jooss, K. & Chan, T. A. Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol. 39, 536–548 (2018).

pubmed: 29751996 pmcid: 7954132 doi: 10.1016/j.it.2018.04.005

Chandran, S. S. et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat. Med. 28, 946–957 (2022).

pubmed: 35484264 pmcid: 9117146 doi: 10.1038/s41591-022-01786-3

Luksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389–395 (2022).

pubmed: 35589842 pmcid: 9177421 doi: 10.1038/s41586-022-04735-9

Wang, Q. L. et al. Association of HLA diversity with the risk of 25 cancers in the UK Biobank. EBioMedicine 92, 104588 (2023).

pubmed: 37148584 pmcid: 10189092 doi: 10.1016/j.ebiom.2023.104588

Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715–1720 (2019).

pubmed: 31700181 pmcid: 7938381 doi: 10.1038/s41591-019-0639-4

Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359, 582 (2018).

pubmed: 29217585 doi: 10.1126/science.aao4572

Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. New Engl. J. Med. 376, 2109–2121 (2017).

McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271.e11 (2017).

pubmed: 29107330 pmcid: 5720478 doi: 10.1016/j.cell.2017.10.001

Bauer, D. C. & Thorne, N. P. et al. Evaluation of computational programs to predict HLA genotypes from genomic sequencing data. Brief. Bioinform. 19, 179–187 (2016).

pmcid: 6019030

Yi, J., Chen, L., Xiao, Y., Zhao, Z. & Su, X. Investigations of sequencing data and sample type on HLA class Ia typing with different computational tools. Brief. Bioinform. 22, bbaa143 (2021).

pubmed: 32662817 doi: 10.1093/bib/bbaa143

Kiyotani, K., Mai, T. H. & Nakamura, Y. Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. J. Hum. Genet. 62, 397–405 (2017).

pubmed: 27881843 doi: 10.1038/jhg.2016.141

Lang, K. et al. Full-length HLA class I genotyping with the MinION nanopore sequencer. Methods Mol. Biol. 1802, 155–162 (2018).

pubmed: 29858807 doi: 10.1007/978-1-4939-8546-3_10

Nielsen, M., Lundegaard, C., Lund, O. & Keşmir, C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57, 33–41 (2005).

pubmed: 15744535 doi: 10.1007/s00251-005-0781-7

Larsen, M. V. et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8, 424 (2007).

pubmed: 17973982 pmcid: 2194739 doi: 10.1186/1471-2105-8-424

Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511–517 (2016).

pubmed: 26515819 doi: 10.1093/bioinformatics/btv639

Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449–W454 (2020).

pubmed: 32406916 pmcid: 7319546 doi: 10.1093/nar/gkaa379

O’Donnell, T. J., Rubinsteyn, A. & Laserson, U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 11, 42–48 e47 (2020).

pubmed: 32711842 doi: 10.1016/j.cels.2020.06.010

Vita, R. et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 47, D339–D343 (2018).

pmcid: 6324067 doi: 10.1093/nar/gky1006

Vizcaíno, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44, 11033 (2016).

pubmed: 27683222 pmcid: 5159556 doi: 10.1093/nar/gkw880

Shao, W. et al. The SysteMHC atlas project. Nucleic Acids Res. 46, D1237–D1247 (2018).

pubmed: 28985418 doi: 10.1093/nar/gkx664

Frahm, N. et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37, 2419–2433 (2007).

pubmed: 17705138 pmcid: 2628559 doi: 10.1002/eji.200737365

Gfeller, D. & Bassani-Sternberg, M. Predicting antigen presentation—what could we learn from a million peptides? Front. Immunol. 9, 1716 (2018).

pubmed: 30090105 pmcid: 6068240 doi: 10.3389/fimmu.2018.01716

Singh-Jasuja, H., Emmerich, N. P. & Rammensee, H. G. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53, 187–195 (2004).

pubmed: 14758508 doi: 10.1007/s00262-003-0480-x

Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014).

pubmed: 25428506 doi: 10.1038/nature14001

Xia, H. et al. Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Sci. Immunol. 8, eabg2200 (2023).

pubmed: 37027480 pmcid: 10450883 doi: 10.1126/sciimmunol.abg2200

Łuksza, M. et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 551, 517–520 (2017).

pubmed: 29132144 pmcid: 6137806 doi: 10.1038/nature24473

Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).

pubmed: 29132146 pmcid: 6145146 doi: 10.1038/nature24462

No authors listed. The problem with neoantigen prediction. Nat. Biotechnol. 35, 97 (2017).

doi: 10.1038/nbt.3800

Jensen, K. K. et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology 154, 394–406 (2018).

pubmed: 29315598 pmcid: 6002223 doi: 10.1111/imm.12889

Zhang, G. L. et al. MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles. J. Immunol. Methods 374, 53–61 (2011).

doi: 10.1016/j.jim.2010.11.009

Guan, P., Hattotuwagama, C. K., Doytchinova, I. A. & Flower, D. R. MHCPred 2.0: an updated quantitative T-cell epitope prediction server. Appl. Bioinformatics 5, 55–61 (2006).

pubmed: 16539539 doi: 10.2165/00822942-200605010-00008

Chen, B. et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat. Biotechnol. 37, 1332–1343 (2019).

pubmed: 31611695 pmcid: 7075463 doi: 10.1038/s41587-019-0280-2

Wang, D. et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol. Syst. Biol. 15, e8503 (2019).

pubmed: 30777892 pmcid: 6379049 doi: 10.15252/msb.20188503

Kalaora, S. et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8, 1366–1375 (2018).

pubmed: 30209080 pmcid: 6453138 doi: 10.1158/2159-8290.CD-17-1418

Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818 (2020).

pubmed: 33038342 pmcid: 7652061 doi: 10.1016/j.cell.2020.09.015

Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 21, 1213–1223 (2020).

pubmed: 32888453 doi: 10.1016/S1470-2045(20)30462-9

Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462 (2019).

pubmed: 30742119 pmcid: 6810613 doi: 10.1038/s41591-019-0349-y

Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).

pubmed: 24120142 pmcid: 3910500 doi: 10.1016/j.cell.2013.09.034

Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

doi: 10.1038/nature07385

Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016).

pubmed: 26928227 doi: 10.1038/ng.3520

Creaney, J. et al. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Med. 14, 58 (2022).

pubmed: 35637530 pmcid: 9150319 doi: 10.1186/s13073-022-01060-8

Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018).

pubmed: 30322867 pmcid: 6310008 doi: 10.1158/2159-8290.CD-18-0804

Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).

pubmed: 28694034 doi: 10.1016/S1470-2045(17)30516-8

Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J. Thorac. Oncol. 14, 276–287 (2019).

pubmed: 30316012 doi: 10.1016/j.jtho.2018.10.001

Yang, W. et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat. Med. 25, 767–775 (2019).

pubmed: 31011208 pmcid: 6558662 doi: 10.1038/s41591-019-0434-2

Kahles, A. et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 34, 211–224.e6 (2018).

pubmed: 30078747 pmcid: 9844097 doi: 10.1016/j.ccell.2018.07.001

Park, J. & Chung, Y. J. Identification of neoantigens derived from alternative splicing and RNA modification. Genomics Inform. 17, e23 (2019).

pubmed: 31610619 pmcid: 6808645 doi: 10.5808/GI.2019.17.3.e23

Shen, L., Zhang, J., Lee, H., Batista, M. T. & Johnston, S. A. RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines. Sci. Rep. 9, 14184 (2019).

pubmed: 31578439 pmcid: 6775166 doi: 10.1038/s41598-019-50738-4

Smart, A. C. et al. Intron retention is a source of neoepitopes in cancer. Nat. Biotechnol. 36, 1056–1058 (2018).

pmcid: 6226333 doi: 10.1038/nbt.4239

Zhang, M. et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat. Commun. 9, 3919 (2018).

pubmed: 30254248 pmcid: 6156571 doi: 10.1038/s41467-018-06405-9

Barczak, W. et al. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response. Nat. Commun. 14, 1078 (2023).

pubmed: 36841868 pmcid: 9968330 doi: 10.1038/s41467-023-36826-0

Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465–478 (2019).

pubmed: 31278396 pmcid: 6874891 doi: 10.1038/s41568-019-0162-4

Chai, S. et al. NeoSplice: a bioinformatics method for prediction of splice variant neoantigens. Bioinform. Adv. 2, vbac032 (2022).

pubmed: 35669345 pmcid: 9154024 doi: 10.1093/bioadv/vbac032

Pan, Y. et al. IRIS: discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc. Natl Acad. Sci. USA 120, e2221116120 (2023).

pubmed: 37192158 pmcid: 10214192 doi: 10.1073/pnas.2221116120

Zhang, Z. et al. ASNEO: identification of personalized alternative splicing based neoantigens with RNA-seq. Aging 12, 14633–14648 (2020).

pubmed: 32697765 pmcid: 7425491 doi: 10.18632/aging.103516

Attig, J. et al. LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly. Genome Res. 29, 1578–1590 (2019).

pubmed: 31537638 pmcid: 6771403 doi: 10.1101/gr.248922.119

Burbage, M. et al. Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements. Sci. Immunol. 8, eabm6360 (2023).

pubmed: 36735776 doi: 10.1126/sciimmunol.abm6360

Merlotti, A. et al. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci. Immunol. 8, eabm6359 (2023).

pubmed: 36735774 doi: 10.1126/sciimmunol.abm6359

Shah, N. M. et al. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat. Genet. 55, 631–639 (2023).

pubmed: 36973455 doi: 10.1038/s41588-023-01349-3

Shi, Y., Jing, B. & Xi, R. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors. Genome Biol. 24, 169 (2023).

pubmed: 37461029 pmcid: 10351168 doi: 10.1186/s13059-023-03005-9

Vensko, S. P. et al. LENS: landscape of effective neoantigens software. Bioinformatics 39, btad322 (2023).

pubmed: 37184881 pmcid: 10246587 doi: 10.1093/bioinformatics/btad322

Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168–182 (2018).

pubmed: 29226910 doi: 10.1038/nri.2017.131

Lang, F., Schrors, B., Lower, M., Tureci, O. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261–282 (2022).

pubmed: 35105974 pmcid: 7612664 doi: 10.1038/s41573-021-00387-y

Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target Ther. 8, 9 (2023).

pubmed: 36604431 pmcid: 9816309 doi: 10.1038/s41392-022-01270-x

Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217 (2017).

pubmed: 28678778 pmcid: 5577644 doi: 10.1038/nature22991

Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).

pubmed: 28678784 doi: 10.1038/nature23003

Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).

pubmed: 30568303 doi: 10.1038/s41586-018-0810-y

Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).

pubmed: 30568305 doi: 10.1038/s41586-018-0792-9

Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112–2119 (2022).

pubmed: 35648703 pmcid: 9531755 doi: 10.1056/NEJMoa2119662

Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).

pubmed: 37165196 pmcid: 10171177 doi: 10.1038/s41586-023-06063-y

Khattak, A. et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. J. Clin. Oncol. 41, LBA9503 (2023).

doi: 10.1200/JCO.2023.41.17_suppl.LBA9503

Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973).

pubmed: 4126434 doi: 10.1038/243290a0

Tognon, C. et al. Expression of the ETV6–NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2, 367–376 (2002).

pubmed: 12450792 doi: 10.1016/S1535-6108(02)00180-0

Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660–664 (2012).

pubmed: 22895193 pmcid: 3690621 doi: 10.1038/nature11282

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

pmcid: 3771322 doi: 10.1038/nature12222

Xiao, X., Garbutt, C. C., Hornicek, F., Guo, Z. & Duan, Z. Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. Cancer Treat. Rev. 63, 61–70 (2018).

pubmed: 29247978 doi: 10.1016/j.ctrv.2017.12.001

Rooper, L. M. et al. DEK-AFF2 carcinoma of the sinonasal region and skull base: detailed clinicopathologic characterization of a distinctive entity. Am. J. Surg. Pathol. 45, 1682–1693 (2021).

pubmed: 34049316 doi: 10.1097/PAS.0000000000001741

Mackall, C. L. et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin. Cancer Res. 14, 4850–4858 (2008).

pubmed: 18676758 pmcid: 2497450 doi: 10.1158/1078-0432.CCR-07-4065

Poorebrahim, M. et al. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential. Cancer Gene Ther. 28, 581–589 (2021).

pubmed: 33654227 pmcid: 8203496 doi: 10.1038/s41417-021-00307-7

Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687–696 (2023).

pubmed: 36356599 doi: 10.1038/s41586-022-05531-1

Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30, R921–R925 (2020).

pubmed: 32810447 pmcid: 8194051 doi: 10.1016/j.cub.2020.06.081

Grisaru-Tal, S., Rothenberg, M. E. & Munitz, A. Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nat. Immunol. 23, 1309–1316 (2022).

pubmed: 36002647 pmcid: 9554620 doi: 10.1038/s41590-022-01291-2

Mensurado, S., Blanco-Dominguez, R. & Silva-Santos, B. The emerging roles of gammadelta T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).

pubmed: 36624304 doi: 10.1038/s41571-022-00722-1

Pittet, M. J., Michielin, O. & Migliorini, D. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402–421 (2022).

pubmed: 35354979 doi: 10.1038/s41571-022-00620-6

Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904 (2008).

pubmed: 18836471 pmcid: 3689267 doi: 10.1038/onc.2008.271

Mihm, M. C., Clemente, C. G. & Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74, 43–47 (1996).

Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).

pubmed: 11229684 doi: 10.1016/S0140-6736(00)04046-0

Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1–14 (2007).

pubmed: 17386080 pmcid: 2265921 doi: 10.1111/j.1365-2567.2007.02587.x

TextXHarjunpää, H., Llort Asens, M., Guenther, C. & Fagerholm, S. C. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol. 10, 1078 (2019).

doi: 10.3389/fimmu.2019.01078

Limagne, E. et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell 40, 136–152.e12 (2022).

pubmed: 35051357 doi: 10.1016/j.ccell.2021.12.009

Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614.e14 (2021).

pubmed: 33508232 pmcid: 7933824 doi: 10.1016/j.cell.2021.01.002

Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559–572 (2017).

pubmed: 28555670 pmcid: 5731833 doi: 10.1038/nri.2017.49

Valkenburg, K. C., de Groot, A. E. & Pienta, K. J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15, 366–381 (2018).

pubmed: 29651130 pmcid: 5960434 doi: 10.1038/s41571-018-0007-1

Waldmann, T. A. Cytokines in cancer immunotherapy. Cold Spring Harb. Perspect. Biol. 10, a028472 (2018).

pubmed: 29101107 pmcid: 6280701 doi: 10.1101/cshperspect.a028472

Maleki Vareki, S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 6, 157 (2018).

pubmed: 30587233 pmcid: 6307306 doi: 10.1186/s40425-018-0479-7

Avila Cobos, F., Alquicira-Hernandez, J., Powell, J. E., Mestdagh, P. & De Preter, K. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat. Commun. 11, 5650 (2020).

pubmed: 33159064 pmcid: 7648640 doi: 10.1038/s41467-020-19015-1

Tran, K. A. et al. Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures. Nat. Commun. 14, 5758 (2023).

pubmed: 37717006 pmcid: 10505141 doi: 10.1038/s41467-023-41385-5

Li, T. et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108 (2017).

pubmed: 29092952 pmcid: 6042652 doi: 10.1158/0008-5472.CAN-17-0307

Mabbott, N. A., Baillie, J. K., Brown, H., Freeman, T. C. & Hume, D. A. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics 14, 632 (2013).

pubmed: 24053356 pmcid: 3849585 doi: 10.1186/1471-2164-14-632

Nirmal, A. J. et al. Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol. Res. 6, 1388–1400 (2018).

pubmed: 30266715 doi: 10.1158/2326-6066.CIR-18-0342

Racle, J. & Gfeller, D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol. Biol. 2120, 233–248 (2020).

pubmed: 32124324 doi: 10.1007/978-1-0716-0327-7_17

Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).

pubmed: 29141660 pmcid: 5688663 doi: 10.1186/s13059-017-1349-1

Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).

pubmed: 27765066 pmcid: 5073889 doi: 10.1186/s13059-016-1070-5

Jimenez-Sanchez, A., Cast, O. & Miller, M. L. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 79, 6238–6246 (2019).

pubmed: 31641033 doi: 10.1158/0008-5472.CAN-18-3560

Finotello, F. et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 11, 34 (2019).

pubmed: 31126321 pmcid: 6534875 doi: 10.1186/s13073-019-0638-6

Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830.e14 (2018).

pubmed: 29628290 pmcid: 5982584 doi: 10.1016/j.immuni.2018.03.023

Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).

pubmed: 31942077 doi: 10.1038/s41586-019-1906-8

M, M. N. et al. Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nat. Commun. 14, 3155 (2023).

doi: 10.1038/s41467-023-38891-x

Chakravarthy, A. et al. Pan-cancer deconvolution of tumour composition using DNA methylation. Nat. Commun. 9, 3220 (2018).

pubmed: 30104673 pmcid: 6089972 doi: 10.1038/s41467-018-05570-1

Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 13, 86 (2012).

pubmed: 22568884 pmcid: 3532182 doi: 10.1186/1471-2105-13-86

Demerath, E. W. et al. Epigenome-wide association study (EWAS) of BMI, BMI change and waist circumference in African American adults identifies multiple replicated loci. Hum. Mol. Genet. 24, 4464–4479 (2015).

pubmed: 25935004 pmcid: 4492394 doi: 10.1093/hmg/ddv161

Rakyan, V. K., Down, T. A., Balding, D. J. & Beck, S. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 12, 529–541 (2011).

pubmed: 21747404 pmcid: 3508712 doi: 10.1038/nrg3000

Koestler, D. C. et al. Improving cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). BMC Bioinformatics 17, 120 (2016).

pubmed: 26956433 pmcid: 4782368 doi: 10.1186/s12859-016-0943-7

Salas, L. A. et al. Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. Nat. Commun. 13, 761 (2022).

pubmed: 35140201 pmcid: 8828780 doi: 10.1038/s41467-021-27864-7

Teschendorff, A. E., Breeze, C. E., Zheng, S. C. & Beck, S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in epigenome-wide association studies. BMC Bioinforma. 18, 105 (2017).

doi: 10.1186/s12859-017-1511-5

Encode Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).

doi: 10.1038/nature11247

Elizabeth Larose, C. et al. Copy number-aware deconvolution of tumor-normal DNA methylation profiles. Preprint at bioRxiv, https://doi.org/10.1101/2020.11.03.366252 (2020).

Flusberg, B. A. et al. Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat. Methods 7, 461–465 (2010).

pubmed: 20453866 pmcid: 2879396 doi: 10.1038/nmeth.1459

Simpson, J. T. et al. Detecting DNA cytosine methylation using nanopore sequencing. Nat. Methods 14, 407–410 (2017).

pubmed: 28218898 doi: 10.1038/nmeth.4184

Sturm, G. et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics 35, i436–i445 (2019).

pubmed: 31510660 pmcid: 6612828 doi: 10.1093/bioinformatics/btz363

Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).

pubmed: 31061481 pmcid: 6610714 doi: 10.1038/s41587-019-0114-2

Wang, X., Park, J., Susztak, K., Zhang, N. R. & Li, M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat. Commun. 10, 380 (2019).

pubmed: 30670690 pmcid: 6342984 doi: 10.1038/s41467-018-08023-x

Jew, B. et al. Accurate estimation of cell composition in bulk expression through robust integration of single-cell information. Nat. Commun. 11, 1971 (2020).

pubmed: 32332754 pmcid: 7181686 doi: 10.1038/s41467-020-15816-6

Chu, T., Wang, Z., Pe’er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505–517 (2022).

pubmed: 35469013 pmcid: 9046084 doi: 10.1038/s43018-022-00356-3

Carroll, T. M. et al. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell 41, 1222–1241.e27 (2023).

pubmed: 37433281 doi: 10.1016/j.ccell.2023.06.006

Menden, K. et al. Deep learning-based cell composition analysis from tissue expression profiles. Sci. Adv. 6, eaba2619 (2020).

pubmed: 32832661 pmcid: 7439569 doi: 10.1126/sciadv.aba2619

Clarke, Z. A. et al. Tutorial: guidelines for annotating single-cell transcriptomic maps using automated and manual methods. Nat. Protoc. 16, 2749–2764 (2021).

pubmed: 34031612 doi: 10.1038/s41596-021-00534-0

Heumos, L. et al. Best practices for single-cell analysis across modalities. Nat. Rev. Genet. 24, 550–572 (2023).

pubmed: 37002403 doi: 10.1038/s41576-023-00586-w

Ahlmann-Eltze, C. & Huber, W. Comparison of transformations for single-cell RNA-seq data. Nat. Methods 20, 665–672 (2023).

pubmed: 37037999 pmcid: 10172138 doi: 10.1038/s41592-023-01814-1

Chen, W. et al. A multicenter study benchmarking single-cell RNA sequencing technologies using reference samples. Nat. Biotechnol. 39, 1103–1114 (2021).

pubmed: 33349700 doi: 10.1038/s41587-020-00748-9

Mallory, X. F., Edrisi, M., Navin, N. & Nakhleh, L. Assessing the performance of methods for copy number aberration detection from single-cell DNA sequencing data. PLoS Comput. Biol. 16, e1008012 (2020).

pubmed: 32658894 pmcid: 7377518 doi: 10.1371/journal.pcbi.1008012

Nguyen, H. C. T., Baik, B., Yoon, S., Park, T. & Nam, D. Benchmarking integration of single-cell differential expression. Nat. Commun. 14, 1570 (2023).

pubmed: 36944632 pmcid: 10030080 doi: 10.1038/s41467-023-37126-3

Zafar, H., Wang, Y., Nakhleh, L., Navin, N. & Chen, K. Monovar: single-nucleotide variant detection in single cells. Nat. Methods 13, 505–507 (2016).

pubmed: 27088313 pmcid: 4887298 doi: 10.1038/nmeth.3835

Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).

pubmed: 33087716 pmcid: 7577981 doi: 10.1038/s41467-020-19119-8

Bohrson, C. L. et al. Linked-read analysis identifies mutations in single-cell DNA-sequencing data. Nat. Genet. 51, 749–754 (2019).

pubmed: 30886424 pmcid: 6900933 doi: 10.1038/s41588-019-0366-2

Dong, X. et al. Accurate identification of single-nucleotide variants in whole-genome-amplified single cells. Nat. Methods 14, 491–493 (2017).

pubmed: 28319112 pmcid: 5408311 doi: 10.1038/nmeth.4227

Huang, Z. et al. Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. Nat. Genet. 54, 492–498 (2022).

pubmed: 35410377 pmcid: 9844147 doi: 10.1038/s41588-022-01035-w

Wu, C. Y. et al. Integrative single-cell analysis of allele-specific copy number alterations and chromatin accessibility in cancer. Nat. Biotechnol. 39, 1259–1269 (2021).

pubmed: 34017141 pmcid: 9127226 doi: 10.1038/s41587-021-00911-w

Broad Institute. inferCNV of the Trinity CTAT Project, https://github.com/broadinstitute/inferCNV (2020).

Muller, S., Cho, A., Liu, S. J., Lim, D. A. & Diaz, A. CONICS integrates scRNA-seq with DNA sequencing to map gene expression to tumor sub-clones. Bioinformatics 34, 3217–3219 (2018).

pubmed: 29897414 pmcid: 7190654 doi: 10.1093/bioinformatics/bty316

Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15

pubmed: 31699795 doi: 10.1158/2159-8290.CD-19-0644

Joanito, I. et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat. Genet. 54, 963–975 (2022).

pubmed: 35773407 pmcid: 9279158 doi: 10.1038/s41588-022-01100-4

Kumar, M., Bowers, R. R. & Delaney, J. R. Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors. Cell Cycle 19, 3154–3166 (2020).

pubmed: 33121339 pmcid: 7714496 doi: 10.1080/15384101.2020.1836439

Kumar, V. et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 12, 670–691 (2022).

pubmed: 34642171 pmcid: 9394383 doi: 10.1158/2159-8290.CD-21-0683

Wu, F. et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat. Commun. 12, 2540 (2021).

pubmed: 33953163 pmcid: 8100173 doi: 10.1038/s41467-021-22801-0

Liu, Y. et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat. Commun. 12, 741 (2021).

pubmed: 33531485 pmcid: 7854640 doi: 10.1038/s41467-021-21043-4

Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).

pubmed: 27124452 pmcid: 4944528 doi: 10.1126/science.aad0501

Demeulemeester, J. et al. Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing. Genome Biol. 17, 250 (2016).

pubmed: 27931250 pmcid: 5146893 doi: 10.1186/s13059-016-1109-7

Gawad, C., Koh, W. & Quake, S. R. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc. Natl Acad. Sci. USA 111, 17947–17952 (2014).

pubmed: 25425670 pmcid: 4273416 doi: 10.1073/pnas.1420822111

Kester, L. et al. Integration of multiple lineage measurements from the same cell reconstructs parallel tumor evolution. Cell Genom. 2, 100096 (2022).

pubmed: 36778661 pmcid: 9903660 doi: 10.1016/j.xgen.2022.100096

Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94 (2011).

pubmed: 21399628 pmcid: 4504184 doi: 10.1038/nature09807

Malikic, S., Jahn, K., Kuipers, J., Sahinalp, S. C. & Beerenwinkel, N. Integrative inference of subclonal tumour evolution from single-cell and bulk sequencing data. Nat. Commun. 10, 2750 (2019).

pubmed: 31227714 pmcid: 6588593 doi: 10.1038/s41467-019-10737-5

Satas, G., Zaccaria, S., Mon, G. & Raphael, B. J. SCARLET: single-cell tumor phylogeny inference with copy-number constrained mutation losses. Cell Syst. 10, 323–332.e8 (2020).

pubmed: 32864481 pmcid: 7451135 doi: 10.1016/j.cels.2020.04.001

Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308.e36 (2018).

pubmed: 29961579 pmcid: 6348010 doi: 10.1016/j.cell.2018.05.060

Kieffer, Y. et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10, 1330–1351 (2020).

pubmed: 32434947 doi: 10.1158/2159-8290.CD-19-1384

Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).

pubmed: 24925914 pmcid: 4123637 doi: 10.1126/science.1254257

Schelker, M. et al. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nat. Commun. 8, 2032 (2017).

pubmed: 29230012 pmcid: 5725570 doi: 10.1038/s41467-017-02289-3

Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274–278 (2020).

pubmed: 32103181 doi: 10.1038/s41586-020-2056-8

Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).

pubmed: 31359002 pmcid: 6689255 doi: 10.1038/s41591-019-0522-3

Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).

pubmed: 29608179 pmcid: 6700744 doi: 10.1038/nbt.4096

Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).

pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048

Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495–502 (2015).

pubmed: 25867923 pmcid: 4430369 doi: 10.1038/nbt.3192

Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21 (2019).

pubmed: 31178118 pmcid: 6687398 doi: 10.1016/j.cell.2019.05.031

Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).

pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0

Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).

pubmed: 34914499 doi: 10.1126/science.abe6474

Alquicira-Hernandez, J., Sathe, A., Ji, H. P., Nguyen, Q. & Powell, J. E. scPred: accurate supervised method for cell-type classification from single-cell RNA-seq data. Genome Biol. 20, 264 (2019).

pubmed: 31829268 pmcid: 6907144 doi: 10.1186/s13059-019-1862-5

Zhang, A. W. et al. Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nat. Methods 16, 1007–1015 (2019).

pubmed: 31501550 pmcid: 7485597 doi: 10.1038/s41592-019-0529-1

Miao, Z. et al. Putative cell type discovery from single-cell gene expression data. Nat. Methods 17, 621–628 (2020).

pubmed: 32424270 doi: 10.1038/s41592-020-0825-9

Brbic, M. et al. MARS: discovering novel cell types across heterogeneous single-cell experiments. Nat. Methods 17, 1200–1206 (2020).

pubmed: 33077966 doi: 10.1038/s41592-020-00979-3

Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).

pubmed: 28991892 pmcid: 5937676 doi: 10.1038/nmeth.4463

Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309–315 (2017).

pubmed: 28114287 pmcid: 5330805 doi: 10.1038/nmeth.4150

Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).

pubmed: 24658644 pmcid: 4122333 doi: 10.1038/nbt.2859

Saelens, W., Cannoodt, R., Todorov, H. & Saeys, Y. A comparison of single-cell trajectory inference methods. Nat. Biotechnol. 37, 547–554 (2019).

pubmed: 30936559 doi: 10.1038/s41587-019-0071-9

Wolf, F. A. et al. PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol. 20, 59 (2019).

pubmed: 30890159 pmcid: 6425583 doi: 10.1186/s13059-019-1663-x

Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 19, 477 (2018).

pubmed: 29914354 pmcid: 6007078 doi: 10.1186/s12864-018-4772-0

Cannoodt, R. et al. SCORPIUS improves trajectory inference and identifies novel modules in dendritic cell development. Preprint at bioRxiv, https://doi.org/10.1101/079509 (2016).

Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).

pubmed: 33597522 pmcid: 7889871 doi: 10.1038/s41467-021-21246-9

Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 15, 1484–1506 (2020).

pubmed: 32103204 doi: 10.1038/s41596-020-0292-x

Giladi, A. et al. Dissecting cellular crosstalk by sequencing physically interacting cells. Nat. Biotechnol. 38, 629–637 (2020).

pubmed: 32152598 doi: 10.1038/s41587-020-0442-2

Chandran, S. S. & Klebanoff, C. A. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol. Rev. 290, 127–147 (2019).

pubmed: 31355495 pmcid: 7027847 doi: 10.1111/imr.12772

Pai, J. A. & Satpathy, A. T. High-throughput and single-cell T cell receptor sequencing technologies. Nat. Methods 18, 881–892 (2021).

pubmed: 34282327 pmcid: 9345561 doi: 10.1038/s41592-021-01201-8

Jin, X. et al. Identification of shared characteristics in tumor-infiltrating T cells across 15 cancers. Mol. Ther. Nucleic Acids 32, 189–202 (2023).

pubmed: 37096165 pmcid: 10122023 doi: 10.1016/j.omtn.2023.03.007

Song, L. et al. Comprehensive characterizations of immune receptor repertoire in tumors and cancer immunotherapy studies. Cancer Immunol. Res. 10, 788–799 (2022).

pubmed: 35605261 pmcid: 9299271 doi: 10.1158/2326-6066.CIR-21-0965

Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 23, 295–316 (2023).

pubmed: 37046001 doi: 10.1038/s41568-023-00560-y

Pai, J. A. et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell 41, 776–790.e77 (2023).

pubmed: 37001526 pmcid: 10563767 doi: 10.1016/j.ccell.2023.03.009

Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).

pubmed: 25924071 doi: 10.1038/nmeth.3364

Marcou, Q., Mora, T. & Walczak, A. M. High-throughput immune repertoire analysis with IGoR. Nat. Commun. 9, 561 (2018).

pubmed: 29422654 pmcid: 5805751 doi: 10.1038/s41467-018-02832-w

Song, L. et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat. Methods 18, 627–630 (2021).

pubmed: 33986545 pmcid: 9328942 doi: 10.1038/s41592-021-01142-2

Kugel, C. H. III et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347–5356 (2018).

pubmed: 29898988 pmcid: 6324578 doi: 10.1158/1078-0432.CCR-18-1116

Jang, S. R. et al. Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma. JAMA Netw. Open 4, e2136823 (2021).

pubmed: 34854905 pmcid: 8640892 doi: 10.1001/jamanetworkopen.2021.36823

Olateju, O. A. et al. Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: a Texas study. Front. Oncol. 12, 1092355 (2022).

pubmed: 36698397 doi: 10.3389/fonc.2022.1092355

Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).

pubmed: 28104840 pmcid: 5592794 doi: 10.1126/science.aaf8399

Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174 (2009).

pubmed: 19197294 pmcid: 2828349 doi: 10.1038/nri2506

Arihara, F. et al. Increase in CD14

pubmed: 23764929 doi: 10.1007/s00262-013-1447-1

Yang, G. et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget 8, 38378–38388 (2017).

pubmed: 28418913 pmcid: 5503539 doi: 10.18632/oncotarget.16386

Facciabene, A., Motz, G. T. & Coukos, G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162–2171 (2012).

pubmed: 22549946 pmcid: 3342842 doi: 10.1158/0008-5472.CAN-11-3687

Saito, T. et al. Two FOXP3

pubmed: 27111280 doi: 10.1038/nm.4086

Petersen, R. P. et al. Tumor infiltrating Foxp3

pubmed: 17099880 doi: 10.1002/cncr.22282

Shimizu, K. et al. Tumor-infiltrating Foxp3

pubmed: 20234320 doi: 10.1097/JTO.0b013e3181d60fd7

Pathria, P., Louis, T. L. & Varner, J. A. Targeting tumor-associated macrophages in cancer. Trends Immunol. 40, 310–327 (2019).

pubmed: 30890304 doi: 10.1016/j.it.2019.02.003

Tiainen, S. et al. High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66, 873–883 (2015).

pubmed: 25387851 doi: 10.1111/his.12607

Zhang, H. et al. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer 18, 740–750 (2015).

pubmed: 25231913 doi: 10.1007/s10120-014-0422-7

Lozano, A. X. et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 353–362 (2022).

pubmed: 35027754 pmcid: 8866214 doi: 10.1038/s41591-021-01623-z

Valpione, S. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat. Commun. 12, 4098 (2021).

pubmed: 34215730 pmcid: 8253860 doi: 10.1038/s41467-021-24343-x

NCI. Cancer Immunotherapy Clinical Trials, https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/pembrolizumab (2022).

Richard, C. et al. Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients. Clin. Cancer Res. 25, 957–966 (2019).

pubmed: 30154227 doi: 10.1158/1078-0432.CCR-18-1940

Bareche, Y. et al. Leveraging big data of immune checkpoint blockade response identifies novel potential targets. Ann. Oncol. 33, 1304–1317 (2022).

pubmed: 36055464 doi: 10.1016/j.annonc.2022.08.084

Khan, M. A. W., Ologun, G., Arora, R., McQuade, J. L. & Wargo, J. A. Gut microbiome modulates response to cancer immunotherapy. Dig. Dis. Sci. 65, 885–896 (2020).

pubmed: 32067144 pmcid: 7678709 doi: 10.1007/s10620-020-06111-x

Lecuelle, J. et al. MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. J. Immunother. Cancer 10, e004241 (2022).

pubmed: 35277462 pmcid: 8919440 doi: 10.1136/jitc-2021-004241

Johannet, P. et al. Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clin. Cancer Res. 27, 131–140 (2021).

pubmed: 33208341 doi: 10.1158/1078-0432.CCR-20-2415

Gohil, S. H., Iorgulescu, J. B., Braun, D. A., Keskin, D. B. & Livak, K. J. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 244–256 (2021).

pubmed: 33277626 doi: 10.1038/s41571-020-00449-x

Gonzalez-Silva, L., Quevedo, L. & Varela, I. Tumor functional heterogeneity unraveled by scRNA-seq technologies. Trends Cancer 7, 265 (2021).

pubmed: 33596415 doi: 10.1016/j.trecan.2021.02.001

Grimes, S. M. Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer. NAR Cancer 5, zcad034 (2023).

pubmed: 37435532 pmcid: 10331933 doi: 10.1093/narcan/zcad034

Singh, M. et al. High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. Nat. Commun. 10, 3120 (2019).

pubmed: 31311926 pmcid: 6635368 doi: 10.1038/s41467-019-11049-4

Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813–823 (2023).

pubmed: 36856617 pmcid: 10410527 doi: 10.1056/NEJMoa2211437

Benson, D. A. et al. GenBank. Nucleic Acids Res. 41, D36–D42 (2013).

pubmed: 23193287 doi: 10.1093/nar/gks1195

Sidhom, J.-W. et al. ImmunoMap: a bioinformatics tool for T-cell repertoire analysis. Cancer Immunol. Res. 6, 151–162 (2018).

pubmed: 29263161 doi: 10.1158/2326-6066.CIR-17-0114

Shugay, M. et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput. Biol. 11, e1004503 (2015).

pubmed: 26606115 pmcid: 4659587 doi: 10.1371/journal.pcbi.1004503

Canzar, S., Neu, K. E., Tang, Q., Wilson, P. C. & Khan, A. A. BASIC: BCR assembly from single cells. Bioinformatics 33, 425–427 (2017).

pubmed: 28172415 doi: 10.1093/bioinformatics/btw631

Lindeman, I. et al. BraCeR: B-cell-receptor reconstruction and clonality inference from single-cell RNA-seq. Nat. Methods 15, 563–565 (2018).

pubmed: 30065371 doi: 10.1038/s41592-018-0082-3

Mandric, I. et al. Profiling immunoglobulin repertoires across multiple human tissues using RNA sequencing. Nat. Commun. 11, 3126 (2020).

pubmed: 32561710 pmcid: 7305308 doi: 10.1038/s41467-020-16857-7

Carter, J. A., Gilbo, P. & Atwal, G. S. IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 25, 1833–1835 (2019).

pubmed: 31806907 doi: 10.1038/s41591-019-0671-4

Auslander, N., Lee, J. S. & Ruppin, E. Reply to: ‘IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma’. Nat. Med. 25, 1836–1838 (2019).

pubmed: 31806908 doi: 10.1038/s41591-019-0646-5

Thompson, J. C. et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 139, 1–8 (2020).

pubmed: 31683225 doi: 10.1016/j.lungcan.2019.10.012

Raghav, K. et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 11, 2738–2747 (2021).

pubmed: 34261675 doi: 10.1158/2159-8290.CD-21-0331

Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).

pubmed: 25970248 doi: 10.1038/nature14404

Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 38, 489–499.e3 (2020).

pubmed: 32916128 doi: 10.1016/j.ccell.2020.08.007

Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318–327 (2019).

pubmed: 30557521 doi: 10.1200/JCO.2018.78.2276

Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).

pubmed: 29443960 pmcid: 6028240 doi: 10.1038/nature25501

Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706–1714 (2019).

pubmed: 31686036 doi: 10.1038/s41591-019-0628-7

Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248–262 (2017).

pubmed: 28052254 doi: 10.1016/j.celrep.2016.12.019

Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).

pubmed: 30894752 pmcid: 6954100 doi: 10.1038/s41586-019-1032-7

Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018).

pubmed: 30127393 pmcid: 6487502 doi: 10.1038/s41591-018-0136-1

Campbell, K. M. et al. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell 41, 791–806.e4 (2023).

pubmed: 37037616 doi: 10.1016/j.ccell.2023.03.010

Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540–3550 (2017).

pubmed: 28487385 doi: 10.1158/0008-5472.CAN-16-3556

Bentham, R. et al. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature 597, 555–560 (2021).

pubmed: 34497419 doi: 10.1038/s41586-021-03894-5

Lu, T. et al. Netie: inferring the evolution of neoantigen-T cell interactions in tumors. Nat. Methods 19, 1480–1489 (2022).

pubmed: 36303017 pmcid: 10083098 doi: 10.1038/s41592-022-01644-7

Computational immunogenomic approaches to predict response to cancer immunotherapies.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Venkateswar Addala (V)

Felicity Newell (F)

John V Pearson (JV)

Alec Redwood (A)

Bruce W Robinson (BW)

Jenette Creaney (J)

Nicola Waddell (N)

Classifications MeSH